Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach ...

Financial writer recommends buying Corbus Pharmaceutical (CRBP) after stock plunges on Novo Nordisk's obesity drug data.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

A dark-money group has launched a multi-state bus tour to bring awareness to what they characterize as bad behavior by pharma ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...